UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1015-12
Program Prior Authorization/Notification
Medication Caprelsa® (vandetanib)
P&T Approval Date 9/2011, 8/2012, 7/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018,
9/2019, 9/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or
progressive medullary thyroid cancer in patients with unresectable locally advanced or
metastatic disease. The National Cancer Comprehensive Network (NCCN) recommends use of
Caprelsa for the treatment of medullary, follicular, oncocytic, and papillary carcinomas.
Caprelsa may be used in patients with indolent, asymptomatic or slowly progressing disease
after careful consideration of the treatment related risks.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Caprelsa will be approved based on the following criterion:
(1) Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Thyroid Carcinoma
1. Initial Authorization
a. Caprelsa will be approved based on one of the following:
(1) All of the following criteria:
(a) Diagnosis of medullary thyroid cancer (MTC)
© 2024 UnitedHealthcare Services, Inc.
1
-AND-
(b) One of the following:
i. Unresectable locoregional disease that is symptomatic or progressing
ii. Asymptomatic recurrent or persistent distant metastatic disease if
unresectable and progressing
iii. Recurrent or persistent distant metastases if symptomatic disease or
progression
-OR-
(2) All of the following:
(a) One of the following diagnoses:
i. Follicular Carcinoma
ii. Oncocytic Carcinoma
iii. Papillary Carcinoma
-AND-
(b) One of the following:
i. Unresectable recurrent
ii. Persistent locoregional disease
iii. Metastatic disease
-AND-
(c) One of the following:
i. Patient has symptomatic disease
ii. Patient has progressive disease
-AND-
(d) Disease is refractory to radioactive iodine treatment
Authorization will be issued for 12 months.
2. Reauthorization
a. Caprelsa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Caprelsa
therapy
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
2
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Caprelsa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed
August 28, 2024.
Program Prior Authorization/Notification – Caprelsa® (vandetanib)
Change Control
8/2014 Annual review with no changes to the coverage criteria. Updated
formatting, Background and References.
8/2015 Annual review. Added coverage for follicular, Hurthle Cell and
papillary carcinomas per NCCN. Updated medullary carcinoma criteria.
Updated background and references.
7/2016 Annual review. Revised criteria for thyroid carcinoma. Updated
formatting, background and references.
7/2017 Annual review. Added criteria for NSCLC. Updated references.
7/2018 Annual review. Revised criteria for medullary thyroid cancer. Updated
references.
9/2019 Annual review with no changes to the coverage criteria. Updated
references. Added general NCCN recommended review criteria.
9/2020 Annual review with no changes to coverage criteria. Updated
references.
10/2021 Annual review with no changes to coverage criteria. Updated
references.
10/2022 Annual review. Updated background and removed criteria for NSCLC
as no longer recommended by NCCN. Added state mandate. Updated
references.
© 2024 UnitedHealthcare Services, Inc.
3
10/2023 Annual review. Updated hürthle cell carcinoma to oncocytic carcinoma.
Updated references.
10/2024 Annual review. Updated criteria for medullary thyroid carcinoma.
Updated references.
© 2024 UnitedHealthcare Services, Inc.
4